⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,122.24
−0.08%
Brent
$109.08
−0.12%
BTC
$82,914.54
+1.31%
ETH
$2,454.40
+2.05%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,122.24
−0.08%
Brent
$109.08
−0.12%
BTC
$82,914.54
+1.31%
ETH
$2,454.40
+2.05%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› SPTX
S
Seaport Therapeutics Inc
NAS:SPTX
Healthcare
nasdaq_composite
$19.28
+8.38%
At close
At close · Wed 21 Oct · ≈
AED 70.81
· Market cap
$1.03B
· Next earnings
Mon 2 Nov
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Seaport Therapeutics Inc · News · TradingHolo
SPTX news
Headlines tagged to this company
DO
Seaport Therapeutics Price Target Announced at $28.00/Share by Canaccord Genuity
Dow Jones Newswires · 6 d ago
BU
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BusinessWire · 11 d ago
LO
RCS - PureTech Health PLC - PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP
London Stock Exchange · 11 d ago
TR
Seaport Therapeutics, Inc. (SPTX) Reports Phase 1 PK Showing 6.8x Bioavailability for GlyphAgo
TradingView · 11 d ago
BU
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BusinessWire · 12 d ago
TR
Seaport Therapeutics, Inc. (SPTX) Posts Phase 1 PK Data Showing 6.8x Bioavailability
TradingView · 12 d ago
DO
Seaport Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones Newswires · 13 d ago
TR
HC Wainwright & Co. reiterates Buy rating on Seaport Therapeutics, $50 price target
TradingView · 13 d ago
BU
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BusinessWire · 13 d ago
LO
RCS - PureTech Health PLC - PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated
London Stock Exchange · 13 d ago
BU
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BusinessWire · 14 d ago
TR
Seaport Therapeutics, Inc. (SPTX) Starts Phase 2a Trial of GlyphAgo in GAD
TradingView · 14 d ago
SE
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation
Seeking Alpha · 70 d ago
BU
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Business Wire · 79 d ago
End of the feed